The increased angiogenesis observed in malignant cells, facilitated by growth factors such as vascular endothelial growth factor (VEGF), is essential for tumor growth and metastasis, making it a key target for HCC therapies [31,32]. The gene discussed is VEGFA; the disease is neoplasm.